Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension
Open Access
- 5 August 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 52 (5), 1783-1790
- https://doi.org/10.1002/hep.23893
Abstract
Terlipressin is frequently used in acute variceal bleeding due to its powerful effect on vasopressin V1 receptors. Although terlipressin is also a partial agonist of renal vasopressin V2 receptors, its effects on serum sodium concentration have not been specifically investigated. To examine the effects of terlipressin on serum sodium concentration in patients with acute portal-hypertensive bleeding, 58 consecutive patients with severe portal-hypertensive bleeding treated with terlipressin were investigated. In the whole population, serum sodium decreased from 134.9 ± 6.6 mEq/L to 130.5 ± 7.7 mEq/L (P = 0.002). Thirty-nine patients (67%) had a decrease in serum sodium ≥ 5 mEq/L during treatment: in 18 patients (31%), between 5 and 10 mEq/L and in 21 patients (36%), greater than 10 mEq/L. In this latter group, serum sodium decreased from 137.2 ± 5 to 120.5 ± 5 mEq/L (P < 0.001). In multivariate analysis, the reduction in serum sodium was related to baseline serum sodium and Model for End-Stage Liver Disease (MELD) score; patients with low MELD and normal or near-normal baseline serum sodium had the highest risk of hyponatremia. Serum sodium returned to baseline values in most patients shortly after cessation of therapy. Three of the 21 patients with marked reduction in serum sodium developed neurological manifestations, including osmotic demyelination syndrome in one patient due to a rapid recovery of serum sodium (serum sodium in these three patients decreased from 135, 130, and 136 to 117, 114, and 109 mEq/L, respectively). Conclusion: An acute reduction in serum sodium concentration is common during treatment with terlipressin for severe portal-hypertensive bleeding. It develops rapidly after start of therapy, may be severe in some patients and is associated with neurological complications, and is usually reversible after terlipressin withdrawal. (HEPATOLOGY 2010Keywords
This publication has 25 references indexed in Scilit:
- Management of Varices and Variceal Hemorrhage in CirrhosisNew England Journal of Medicine, 2010
- Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varicesGut, 2009
- Effects of terlipressin on the aquaretic system: evidence of antidiuretic effectsAmerican Journal of Physiology-Renal Physiology, 2008
- Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and managementHepatology, 2008
- MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantationGut, 2007
- Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology, 2007
- Terlipressin causing a hyponatraemic seizureScandinavian Journal of Gastroenterology, 2007
- Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2005
- Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early deathHepatology, 2004
- Time profile of the haemodynamic effects of terlipressin in portal hypertensionJournal of Hepatology, 1997